Margetuximab

(Margenza®)

Margenza®

Drug updated on 12/19/2023

Dosage FormInjection (intravenous: 250 mg/10 mL (25 mg/mL))
Drug ClassHER2/neu receptor antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Margenza (margetuximab-cmkb) Prescribing Information.2020MacroGenics, Inc., Rockville, MD

Randomized Controlled Trials

Clinical Practice Guidelines